Biospecimen Acquisition, Processing and Classification Unit

项目摘要(生物质学股) MSKCC是世界上最大和最繁忙的癌症中心之一，处于支持 综合人体肿瘤图集的生成。MSKCC每年都会看到超过620,000 门诊，进行了21,000多次手术，并进行了46,000多次诊断和 介入放射学程序。总体而言，这些资源优势表明我们拥有 患者数量和专业知识，以获得全面分析所需的样本 从原发肿瘤到转移瘤的过渡。这项提议寻求对产生 肺癌、胰腺癌和中枢神经系统转移综合图集。这些代表了 常见的临床情景、未得到满足的关键需求以及MSKCC已经存在的领域 深入而广泛的研究计划。因此，这个生物科学单位的目标是获取、注释 并提供高质量的生物标本，以支持这三个地图集的创建。首先，我们将 从手术切除或肺活检材料中建立预期的、高质量的生物信息库 癌症、胰腺癌和中枢神经系统转移，目标是获得时间信息 关于原发肿瘤类型向转移类型的转变。接下来，我们将建立一个高质量的 肺癌、胰腺癌或中枢神经系统患者死后衍生组织生物库 通过研究(温暖)尸检程序进行转移。这种方法将允许收集两者 从原发肿瘤类型到转移的时间和空间信息 同一个体的不同器官部位。最后，我们将优化隔离方法 单个细胞，并基于基本原理与合作机构交叉验证这些方法 单细胞分离的最佳方法可能是组织类型和背景特定的。最终， 我们的目标是为这些和其他肿瘤类型的合作努力和未来计划的研究提供信息 通过Htan。

PROJECT SUMMARY (Biospecimen Unit) MSKCC is one of the largest and busiest cancer centers in the world, ideally positioned to support generation of comprehensive Human Tumor Atlases. On an annual basis MSKCC sees over 620,000 outpatient visits, performs over 21,000 surgeries, and conducts over 460,000 diagnostic and interventional radiology procedures. Collectively, these resource strengths indicate we have the patient volumes and expertise to obtain the samples required for comprehensive profiling of the transition from a primary tumor to metastasis. This proposal seeks support for the generation of comprehensive atlases of Lung Cancer, Pancreatic Cancer, and CNS Metastases. These represent common clinical scenarios, critical unmet needs, and areas in which MSKCC already has existing deep and broad research programs. Thus, the goal of this Biospecimen Unit is to acquire, annotate and supply high quality biospecimens to support creation of these three Atlases. First, we will establish a prospective, high quality biorepository from surgically resected or biopsy materials of lung cancer, pancreatic cancer and CNS metastases with the goal of obtaining temporal information regarding the transition from primary tumor type to metastasis. Next, we will establish a high quality biorepository of postmortem derived tissues of patients with lung cancer, pancreatic cancer or CNS metastasis through a research (warm) autopsy program. This approach will allow collection of both temporal and spatial information regarding the transition from primary tumor type to metastasis in different organ sites in the same individual. Finally, we will optimize methodologies for isolation of single cells and cross validate these methods with collaborating institutions based on the rationale that the optimal methods for single cell isolation are likely tissue-type and context specific. Ultimately, we aim to inform collaborative efforts and future planned studies of these and additional tumor types through the HTAN.